Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | CCR3 | P51677 | 2/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.75 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.65 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.65 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.65 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.65 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.63 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.63 |
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867837 | 0.98 | KCNH2 (1.00) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| Hydrochloric Acid SCHEMBL7321952 | 0.98 | KCNH2 (0.94) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12040797 | 0.98 | KCNH2 (1.00) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL153896 | 0.95 | KCNH2 (0.88) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041264 | 0.91 | KCNH2 (0.81) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041389 | 0.90 | KCNH2 (0.84) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041391 | 0.90 | KCNH2 (0.84) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12040811 | 0.90 | KCNH2 (0.84) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041393 | 0.90 | KCNH2 (0.84) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 | |
| SCHEMBL12041232 | 0.89 | KCNH2 (0.78) | KCNH2CCR3SIGMAR1PRMT6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| CN-102293773-A | Drug with benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORP | 2011-12-28 | — | — | CN | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719768-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2006-11-08 | — | — | EP | disclosed |
| CN-1678597-A | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORP (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | KCNH2 818/4885CCR3 4380/4885SIGMAR1 932/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | KCNH2 1289/4885CCR3 4680/4885SIGMAR1 205/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | KCNH2 1355/4885CCR3 4379/4885SIGMAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.